investor-day-2021-notext

2024 Virtual Annual Meeting of Shareholders

Learn more
blue-gradient

2023 Investor Day

Find out more
investor-day-2021-notext

Business Transformation-Linked Financing Framework

Learn more

 

 

Investor kit

Download All
  • PMI Investor Information March 2024

    .pdf

    18/03/2024

  • 2023 Annual Report

    .pdf

    28/03/2024

  • 2023 Integrated Report

    .pdf

    28/03/2024

  • 2024 Proxy Statement

    .pdf

    28/03/2024

  • 2021-23 Recast Shipment Volume & Financial Information by Region

    .pdf

    27/02/2024

James Bushnell_
We are investing behind innovation and delivering sustainable growth from our leading smoke-free products, which are a much better choice than continued smoking. 
James Bushnell, Vice President, Investor Relations & Financial Communications 

Why invest in PMI?

Philip Morris International is leading a transformation in the tobacco industry to create a smoke-free future, and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, as well as to society, the company, and its shareholders. PMI is building its future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its products meet adult consumer preferences and rigorous regulatory requirements.

ginza-store

Global market profile

We are engaged in the manufacture and sale of cigarettes and smoke-free products in more than 180 markets around the world.
Who we are

An unparalleled portfolio of brands

Our brand portfolio is led by Marlboro, the world’s best-selling international cigarette. Our leading smoke-free product, IQOS, is typically marketed with consumables under the brand names TEREA, HEETS, and others. Based on the strength of our brand portfolio, we enjoy robust pricing power.

 

scienceinnovation-half-image

Leading-edge research and development

One of our key strategic priorities is to develop, assess, and commercialize a portfolio of innovative tobacco and other nicotine-containing products. We draw on the expertise of a team of world-class scientists from a broad spectrum of disciplines to help us reach our ultimate goal of replacing cigarettes with less harmful alternatives.
Our science

 

Delivering a smoke-free future in a sustainable way

Replacing cigarettes with less harmful alternatives is at the core of our business strategy, and sits atop our sustainability priorities. Find out more about PMIs transformation, and our approach to sustainability.

 

*Reduced Risk Products (RRPs) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking.  PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.